Research graph
References from Mechanistic insights into VSIR-mediated AXL regulation and gastric cancer proliferation. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 · External reference
Helicobacter pylori infection and the development of gastric cancer
10.1056/nejmoa001999 · 2001 · External reference
Helicobacter pylori-Mediated Immunity and Signaling Transduction in Gastric Cancer
10.3390/jcm9113699 · 2020 · External reference
Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers
10.1111/cas.12205 · 2013 · External reference
IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3
10.4049/jimmunol.1002971 · 2011 · External reference
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
10.1016/j.ccr.2009.01.001 · 2009 · External reference
Targeted Therapies and Developing Precision Medicine in Gastric Cancer
10.3390/cancers15123248 · 2023 · External reference
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(10)61121-x · 2010 · External reference
VISTA-mediated immune evasion in cancer
10.1038/s12276-024-01336-6 · 2024 · External reference
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
10.1126/science.aay0524 · 2020 · External reference
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
10.1007/s00262-018-2227-8 · 2018 · External reference
FOXD3 Regulates VISTA Expression in Melanoma
10.1016/j.celrep.2019.12.036 · 2020 · External reference
VISTA expression and patient selection for immune-based anticancer therapy
10.3389/fimmu.2023.1086102 · 2023 · External reference
Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer
10.1002/ctm2.1578 · 2024 · External reference
IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
10.1186/s40364-022-00394-0 · 2022 · External reference
AXL in cancer: a modulator of drug resistance and therapeutic target
10.1186/s13046-023-02726-w · 2023 · External reference
A novel putative tyrosine kinase receptor with oncogenic potential
1991 · External reference
AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma
2018 · External reference
AXL kinase as a novel target for cancer therapy
10.18632/oncotarget.2542 · 2014 · External reference
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.lungcan.2023.107291 · 2023 · External reference
AXL signaling in cancer: from molecular insights to targeted therapies
10.1038/s41392-024-02121-7 · 2025 · External reference
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
10.3390/cancers14030466 · 2022 · External reference
Gas6/AXL pathway: immunological landscape and therapeutic potential
10.3389/fonc.2023.1121130 · 2023 · External reference
The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact
10.3390/medicina61091619 · 2025 · External reference
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
10.1007/s10120-020-01066-4 · 2020 · External reference
Association Between Phosphorylated AXL Expression and Survival in Patients with Gastric Cancer
10.3390/jcm13226694 · 2024 · External reference
A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment
10.1002/mco2.11 · 2020 · External reference
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
10.1038/s41467-018-08074-0 · 2019 · External reference
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
10.3390/cancers12071850 · 2020 · External reference
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
10.1016/j.it.2020.12.008 · 2021 · External reference
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
10.1038/s41591-023-02465-7 · 2023 · External reference
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
10.1038/npjbcancer.2016.33 · 2016 · External reference
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
10.1158/1535-7163.mct-19-0873 · 2020 · External reference
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors
10.1021/acs.jmedchem.2c01346 · 2022 · External reference
The Lupus Susceptibility Locus Sgp3 Encodes the Suppressor of Endogenous Retrovirus Expression SNERV
10.1016/j.immuni.2018.12.022 · 2019 · External reference
Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer
10.1002/ctm2.1578 · ExternalCitation · doi-reference
A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment
10.1002/mco2.11 · ExternalCitation · doi-reference
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
10.1007/s00262-018-2227-8 · ExternalCitation · doi-reference
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
10.1007/s10120-020-01066-4 · ExternalCitation · doi-reference
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
10.1016/j.ccr.2009.01.001 · ExternalCitation · doi-reference
FOXD3 Regulates VISTA Expression in Melanoma
10.1016/j.celrep.2019.12.036 · ExternalCitation · doi-reference
The Lupus Susceptibility Locus Sgp3 Encodes the Suppressor of Endogenous Retrovirus Expression SNERV
10.1016/j.immuni.2018.12.022 · ExternalCitation · doi-reference
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
10.1016/j.it.2020.12.008 · ExternalCitation · doi-reference
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.lungcan.2023.107291 · ExternalCitation · doi-reference
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(10)61121-x · ExternalCitation · doi-reference
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors
10.1021/acs.jmedchem.2c01346 · ExternalCitation · doi-reference
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
10.1038/npjbcancer.2016.33 · ExternalCitation · doi-reference
VISTA-mediated immune evasion in cancer
10.1038/s12276-024-01336-6 · ExternalCitation · doi-reference
AXL signaling in cancer: from molecular insights to targeted therapies
10.1038/s41392-024-02121-7 · ExternalCitation · doi-reference
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
10.1038/s41467-018-08074-0 · ExternalCitation · doi-reference
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
10.1038/s41591-023-02465-7 · ExternalCitation · doi-reference
Helicobacter pylori infection and the development of gastric cancer
10.1056/nejmoa001999 · ExternalCitation · doi-reference
Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers
10.1111/cas.12205 · ExternalCitation · doi-reference
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
10.1126/science.aay0524 · ExternalCitation · doi-reference
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
10.1158/1535-7163.mct-19-0873 · ExternalCitation · doi-reference
AXL in cancer: a modulator of drug resistance and therapeutic target
10.1186/s13046-023-02726-w · ExternalCitation · doi-reference
IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
10.1186/s40364-022-00394-0 · ExternalCitation · doi-reference
AXL kinase as a novel target for cancer therapy
10.18632/oncotarget.2542 · ExternalCitation · doi-reference
VISTA expression and patient selection for immune-based anticancer therapy
10.3389/fimmu.2023.1086102 · ExternalCitation · doi-reference
Gas6/AXL pathway: immunological landscape and therapeutic potential
10.3389/fonc.2023.1121130 · ExternalCitation · doi-reference
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
10.3390/cancers12071850 · ExternalCitation · doi-reference
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
10.3390/cancers14030466 · ExternalCitation · doi-reference
Targeted Therapies and Developing Precision Medicine in Gastric Cancer
10.3390/cancers15123248 · ExternalCitation · doi-reference
Association Between Phosphorylated AXL Expression and Survival in Patients with Gastric Cancer
10.3390/jcm13226694 · ExternalCitation · doi-reference
Helicobacter pylori-Mediated Immunity and Signaling Transduction in Gastric Cancer
10.3390/jcm9113699 · ExternalCitation · doi-reference
The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact
10.3390/medicina61091619 · ExternalCitation · doi-reference
IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3
10.4049/jimmunol.1002971 · ExternalCitation · doi-reference
